Company intelligence / Profile preview

Nucleix

Ownership: Private
Development stage: Commercial

Overview

Nucleix’s Bladder EpiCheck test has CE-marking in Europe for primary and recurrent bladder/upper tract urinary cancers, and FDA 510(k) clearance in the US for monitoring bladder cancer recurrence. The company’s blood-based lung EpiCheck test for early-stage lung cancer detection in high-risk individuals remains under development. Clinical data support high sensitivity/specificity of their non-invasive tests.

Therapeutic areas: Oncology
Modalities: Diagnostic test (liquid biopsy)PCR-based epigenetics assayMethylation-based identification
Industry: Molecular Diagnostics

Drug pipeline

2 assets

Bladder EpiCheck

Commercial

Indications: bladder cancer, upper tract urinary cancer

1 more asset in the full pipeline.

Request access →

Partnerships

A. Menarini Diagnostics—for European commercialization of Bladder EpiCheck®

Beyond the preview

Go deeper on Nucleix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nucleix.

Explore the full profile